Clavis Pharma's last shot at success in late-stage cancer drug R&D ended in a decisive failure today, with the Norwegian company reporting that its experimental drug elacytarabine failed to register a significant improvement in overall survival...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.